enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Update

enVVeno Medical Corporation (NASDAQ:NVNO) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 532,700 shares, an increase of 24.7% from the February 13th total of 427,100 shares. Based on an average daily trading volume, of 135,100 shares, the days-to-cover ratio is presently 3.9 days. Currently, 3.1% of the company’s shares are sold short.

enVVeno Medical Trading Down 3.7 %

Shares of NVNO stock traded down $0.11 during trading hours on Tuesday, reaching $2.85. The company’s stock had a trading volume of 86,844 shares, compared to its average volume of 107,560. The stock has a market capitalization of $49.98 million, a P/E ratio of -2.21 and a beta of 1.38. enVVeno Medical has a one year low of $2.45 and a one year high of $6.48. The firm’s fifty day simple moving average is $3.24 and its 200 day simple moving average is $3.46.

enVVeno Medical (NASDAQ:NVNO) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. As a group, equities research analysts forecast that enVVeno Medical will post -1.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enVVeno Medical

Several hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of enVVeno Medical during the fourth quarter valued at approximately $56,000. Northern Trust Corp boosted its position in shares of enVVeno Medical by 68.3% during the fourth quarter. Northern Trust Corp now owns 56,725 shares of the company’s stock valued at $171,000 after purchasing an additional 23,029 shares in the last quarter. Altium Capital Management LLC boosted its position in shares of enVVeno Medical by 29.8% during the fourth quarter. Altium Capital Management LLC now owns 310,000 shares of the company’s stock valued at $936,000 after purchasing an additional 71,080 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of enVVeno Medical during the fourth quarter valued at approximately $147,000. Finally, Geode Capital Management LLC boosted its position in shares of enVVeno Medical by 20.6% during the fourth quarter. Geode Capital Management LLC now owns 181,737 shares of the company’s stock valued at $549,000 after purchasing an additional 31,061 shares in the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).